logo
  

Adamis Says Clinical Trial Start-up Activities Underway For Tempol In Treatment Of COVID-19

Adamis Pharmaceuticals Corp. (ADMP) said Friday that clinical trial start-up activities are underway for examining the effects of its experimental drug, Tempol, in the treatment of COVID-19. The company is carrying out the activities with a large clinical research organization.

In Friday pre-market trade, ADMP was trading at $1.10 up $0.08 or 7.84%.

The commenced activities include site identification and initiation, data base production, vendor management, and the establishment of an independent data safety monitoring board of infectious disease experts, who will review the safety and efficacy of the trial.

The goal of the trial is to examine the safety and activity of Tempol in COVID-19 patients early in the infection. The trial is entitled "A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) on Preventing COVID-19 Related Hospitalization in Subjects with COVID-19 Infection.

Tempol produced a 5 log decrease in virus levels in cells infected with SARS-CoV-2. Tempol performed better in inhibiting RNA replicase than Remdesivir, which has been approved on an emergency use basis for the treatment of COVID-19. Tempol also synergized with Remdesivir.

Adamis has a worldwide license to use Tempol for the treatment of respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT